3,611 reports of this reaction
24.1% of all LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN reports
#2 most reported adverse reaction
ILL DEFINED DISORDER is the #2 most commonly reported adverse reaction for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, manufactured by Novartis Pharmaceuticals Corporation. There are 3,611 FDA adverse event reports linking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN to ILL DEFINED DISORDER. This represents approximately 24.1% of all 14,999 adverse event reports for this drug.
Patients taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN who experience ill defined disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ILL DEFINED DISORDER is a frequently reported adverse event for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, accounting for a significant proportion of all reports.
In addition to ill defined disorder, the following adverse reactions have been reported for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:
The following drugs have also been linked to ill defined disorder in FDA adverse event reports:
ILL DEFINED DISORDER has been reported as an adverse event in 3,611 FDA reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ILL DEFINED DISORDER accounts for approximately 24.1% of all adverse event reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, making it one of the most commonly reported side effect.
If you experience ill defined disorder while taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.